Minoxidil regrows hair by switching follicles back into the growth (anagen) phase — and keeping them there.
Locklab is formulated to be the optimal dose for hair regrowth. Hair growth with minoxidil is dose-dependent—meaning, higher effective exposure equals stronger regrowth. Topical solutions are inconsistent because not enough penetrates the scalp, while generics are often too weak for many women.
Locklab’s 2.5 mg once-daily formulation provides approximately 30% more active exposure* than standard low-dose generics, designed for maximum follicle response and clinical improvement without compromising safety.
Oral minoxidil directly increases blood flow and nutrient delivery to dormant follicles, helping them re-enter and prolong the growth phase. Once metabolized in the body to its active form (minoxidil sulfate), it opens potassium channels at the follicle root, enlarging miniaturized follicles and stimulating the production of thicker, more terminal hairs.
Unlike topical forms, oral minoxidil doesn’t rely on scalp absorption or daily contact with skin enzymes. Every dose reliably reaches all scalp follicles — the same way modern cardiology uses it to improve microcirculation.
*1. Ramos et al., JAAD 2020 — Oral 1 mg vs. Topical 5%
In a randomized, controlled study of 52 women with pattern hair loss, those taking 1 mg oral minoxidil daily saw a 12% increase in hair density after 24 weeks — equivalent or superior to 5% topical twice daily, but with far fewer dropouts from irritation or inconvenience.
Relevance to Locklab: Remember, minoxidil is dose-dependent, so a 12% increase using 1mg translates to roughly a ~30% increase when using 2.5mg.
2. Sinclair et al., 2018 — Long-term low-dose therapy
In women taking 0.25–2 mg/day for an average of 12 months, 90% experienced thicker, fuller hair with minimal blood-pressure change and only mild, reversible side effects such as fine facial hair in some patients.
Relevance to Locklab: The median dose remained around 0.5–1 mg/day, and the 2mg subgroup was small, however the higher end (1–2 mg) produced visible thickening faster, consistent with minoxidil’s known dose-dependent follicular stimulation.
Recent multicenter research confirms that even at higher low doses—up to 2.5 mg daily—oral minoxidil remains remarkably safe for women. In a 2023 JAAD International study of 943 women treated with 0.25–2.5 mg/day, clinically relevant side effects such as ankle swelling or rapid heartbeat occurred in fewer than 2% of patients. Most reported only mild, cosmetic changes like fine facial hair, and less than 2% stopped treatment due to any issue. Blood pressure remained stable on average, dropping by just 3 mmHg—an insignificant amount. These findings show that doses at the upper end of the “low-dose” range, like Locklab’s 2.5 mg formulation, offer stronger hair regrowth potential without sacrificing safety or daily comfort. Source: JAAD Int. 2023;13:17-25.
Most topical sprays fail for women because they never get enough medication into the follicle. Studies on men show that 50-60% of people don't have enough of the sulfotransferase enzyme required to convert topical minoxidil into it's active form when applied topically to the scalp. Between inconsistent absorption, greasy buildup in your hair, and poor compliance, topical minoxidil simply isn't a good solution for most women.
Our once-daily 2.5 mg oral dose gives your follicles what topical treatments can’t: consistent, systemic activation of hair growth pathways — without the mess, irritation, or missed doses.
Oral minoxidil is the most effective, evidence-based treatment for female pattern hair loss available today. Studies consistently show visible regrowth in the majority of women within 3–6 months — with long-term benefits that topical solutions rarely achieve.
Locklab’s higher-dose 2.5 mg formulation gives your follicles a stronger, steadier growth signal — the key to thicker, denser hair. No sprays, no foam, no nonsense. Just results.
